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INTRODUCTION
Studies in rats [1], dogs [2], and rhesus monkeys [3] in the
1960s showed that cyclophosphamide (CY), although non-
myeloablative, was a powerful immunosuppressive agent that
facilitated stable engraftment of transplanted allogeneic
hematopoietic cells. Given these properties and the fact that
aplastic anemia is a nonmalignant disease characterized by an
“empty” marrow, CY seemed well suited to condition patients
with that disorder for allogeneic hematopoietic cell transplan-
tation. CY was introduced into the clinical practice of marrow
transplantation in 1970 [4,5] and has remained a major com-
ponent of many transplantation protocols. The early experi-
ence with CY conditioning in aplastic anemia patients showed
allograft rejection to be a major problem seen in 35% to 60%
of patients [6-9]. Rejection was thought to be due to transfu-
sion-induced sensitization of patients to minor non-HLA
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ABSTRACT
This report summarizes the experience with a conditioning regimen of cyclophosphamide and antithymocyte globu-
lin in patients with severe aplastic anemia given HLA-matched related marrow grafts at 4 transplantation centers.
Enrolled were 94 consecutive patients, of whom 87 had received multiple transfusions and 38 had failed immuno-
suppressive therapy. Their ages ranged from 2 to 59 years. After transplantation, 89 patients received a methotrexate/
cyclosporine regimen for graft-versus-host disease (GVHD) prevention. Cyclosporine with or without prednisone
was given in 4 patients, and no immunosuppression was given in 1 patient. Ninety-six percent of patients had sus-
tained grafts, whereas 4% rejected grafts between 2 and 7 months after transplantation. Of the 4 rejecting patients,
3 are alive with successful second engraftments. Acute grade II GVHD was seen in 21% of patients, grade III in 7%,
and grade IV in 1% of patients. Chronic GVHD was seen in 32% of patients, most of whom responded completely
to immunosuppressive therapy. With a median follow-up of 6.0 years (range, 0.5-11.6 years), the survival rate was
88%. No unusual long-term side effects have been seen with the regimen. We conclude that the cyclophos-
phamide/antithymocyte globulin regimen combined with methotrexate/cyclosporine after transplantation is well
tolerated and effective in heavily pretreated patients with aplastic anemia.
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histocompatibility antigens. This problem was predicted from
studies in a preclinical canine model [10,11]. Subsequent
canine studies showed a combination of an alkylating agent
and antithymocyte globulin (ATG) to be effective in over-
coming transfusion-induced sensitization [12,13]. Based on
these results, we introduced a combination of CY and horse
ATG into clinical transplantation in the late 1970s. First, the
regimen was shown to be successful in conditioning patients
for second marrow transplantations after rejection of their
ﬁrst grafts [14]. Encouraged by these results, we next used
CY/ATG as conditioning for ﬁrst transplantations. In 1994,
we reported initial data with that approach from 39 patients
who experienced a rejection incidence of 5% and an actuarial
survival rate of 92% [15]. Here, we update the early results
and summarize the subsequent experience with this regimen
in patients with severe aplastic anemia given HLA-matched
related marrow grafts at the Fred Hutchinson Cancer
Research Center (FHCRC), the VA Puget Sound Health
Care System (VAPSHCS) in Seattle, Stanford University
(SU), and City of Hope Medical Center (CoHMC).
PATIENTS AND METHODS
Ninety-four consecutive patients were entered in the
CY/ATG transplant protocol between July 13, 1988, and
June 30, 1999. Patient characteristics are listed in the Table.
Marrow donors were genotypically HLA-identical siblings in
92 cases, a phenotypically HLA-identical father in 1 case, and
a monozygous twin in 1 case (this was a second transplantation
with CY/ATG conditioning after rejection of the ﬁrst trans-
plant, which had been administered without conditioning).
Patients were referred after consultation with their
physicians and entered into the study after outpatient and
inpatient conferences that outlined the advantages and dis-
advantages of the transplantation procedure. Protocols and
consent forms were approved by the Institutional Review
Boards of the FHCRC, VAPSHCS, SU, and CoHMC.
Before transplantation, 93 patients received 50 mg/kg
CY intravenously (i.v.) on each of 4 successive days [15]. One
patient with Fanconi anemia was conditioned with 35 mg/kg
i.v. CY on each of 4 days [16]. Twelve hours after the ﬁrst,
second, and third dose of CY, patients were given horse ATG
(Atgam; Upjohn, Kalamazoo, MI) at 30 mg/kg i.v. per dose
infused over a period of 10 to 12 hours. Unmanipulated mar-
row was administered 36 hours after the last dose of CY. The
day of marrow transplantation was designated day 0.
After transplantation, 78 recipients of allogeneic marrow
were treated with a short course of methotrexate (MTX) along
with at least 180 days of cyclosporine (CSP), as described [17].
Eleven patients were given MTX/CSP combined with
methylprednisolone [18]; 4 patients received CSP with or
without methylprednisolone; and 1 patient, who underwent a
second transplantation with a monozygous twin donor, was
not given posttransplantation immunosuppression.
Fifty-ﬁve of the patients were treated in laminar airﬂow
isolation rooms with skin and gut decontamination.
The documentation of allogeneic engraftment and
assessment, and grading and treatment of acute and chronic
graft-versus-host disease (GVHD) were performed as
described [19-21]. Grades II to IV acute GVHD was treated
according to ongoing protocols, which usually included,
2 mg/kg methylprednisolone per day, either i.v. or orally, in
divided doses for a period of 7 to 14 days. Marrow aspirates
were usually carried out on days 28, 56, 84, and 365 after
transplantation and at irregular intervals thereafter to assess
the quality of engraftment and to determine chimerism,
using either cytogenetic studies, in situ hybridization with
Characteristics of Aplastic Anemia Patients in Study
Patients studied, n
FHCRC and Seattle VAPSHCS* 65
City of Hope Medical Center 15
Stanford University 14
Total 94
Median age (range), y 26 (2-59)
Sex (F/M), n 38/56
Possible causes of aplastic anemia, n
Unknown 76
Hepatitis 7
Pregnancy 4
Drugs or chemicals 5
Dyskeratosis congenita 1
Fanconi anemia 1
Median granulocyte count on admission, 290 (0-2516) 
cells/µL (range)
Median platelet count on admission, 21,000 (2000-143,000) 
cells/µL (range)†
Patients with very severe aplastic anemia 37 
(granulocyte count, <200 cells/µL)
Transfused/untransfused patients, n 87/6 (1 unknown)
Patients with preceding transfusions, n
Red blood cells 74 (6 unknown)
Platelets 75 (7 unknown)
Median preceding transfusion, no. of 
units (range)
Red blood cells‡ 5 (1-46)
Platelets§ 12 (1-130)
Patients with refractory to random 7 
donor platelets, n
History of treatment, no. of patients
Antithymocyte globulin 22
Cyclosporine 21
Steroids 32
Androgens 11
Any immunosuppression 38
Granulocyte colony-stimulating factor 17
Median duration of aplastic anemia 2.4 (0.2-146.6)
(range), mo
Cytomegalovirus serostatus of patients, n
Patient–/donor– 14
Patient–/donor+ 6
Patient+/donor– 26
Patient+/donor+ 45
Median no. of marrow cells infused, 2.8 (1.0–9.8)
 108/kg (range)
*FHCRC indicates Fred Hutchinson Cancer Research Center;
VAPSHCS, VA Puget Sound Health Care System.
†Many patients had received transfusions before arrival at the trans-
plantation centers.
‡Exact numbers available in 50 of 74 patients who were all reported
to have received multiple red blood cell transfusions.
§Exact numbers available in 49 of 75 patients who were all reported
to have received multiple platelet transfusions.
Data missing in 3 patients.
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ﬂuorescent probes for repetitive DNA sequences on X and
Y chromosomes, or testing for microsatellite marker poly-
morphisms [22]. Nineteen patients had red blood cell group
differences, which served as additional markers for engraft-
ment. One patient (syngeneic) had no markers.
Results of the study were analyzed as of June 2000. Graft
rejection, acute and chronic GVHD, and survival were the
primary outcomes of interest. Survival curves were plotted
using the methods of Kaplan and Meier [23]. The probabili-
ties of acute GVHD, rejection, survival after acquisition of
chronic GVHD, and discontinuation of immunosuppressive
therapy for chronic GVHD were determined with cumula-
tive incidence estimates [24]. Chronic GVHD was depicted
by a prevalence curve. The prevalence curve takes into
account not only the time of onset of chronic GVHD, but
also the time of its resolution in response to therapy [25].
RESULTS
We did not observe differences in outcome among
patients who underwent transplantation at the various cen-
ters. Of the originally described 39 patients, 36 (92%) are
currently alive.
Engraftment and Graft Rejection
All 93 patients who survived beyond the first 2 weeks
showed evidence of hematopoietic engraftment as deter-
mined by rising peripheral blood cell counts, return of mar-
row cellularity, and blood genetic marker studies.
Four patients rejected their marrow grafts, which trans-
lated into a 4% probability of rejection (Figure 1A). One
patient rejected his graft during the first 2 months, and 3
rejected grafts between 6 and 7 months. All 4 patients had
received previous transfusions of blood products. No other
consistent risk factors for rejection could be identiﬁed, such
as low marrow cell dose or a predominance of male-to-
female grafts. All 4 patients underwent second transplanta-
tions from the same donors, and 3 are alive between 6.5 and
10 years after the initial transplantation. One patient who
was not conditioned for the second transplantation died
from infection 6.5 months after the first transplantation,
within a day of the second transplantation. The other
3 patients received conditioning regimens for second trans-
plantations: 2 patients were conditioned with CY and 12 Gy
fractionated total body irradiation, and 1 patient was condi-
tioned with monoclonal antibody to CD3 combined with
high-dose methylprednisolone [26].
So far, 55 of the 83 surviving patients (66%) have returned
to the transplantation centers for follow-up studies between
approximately 1 and 6.5 years. Chimerism evaluations showed
a median of 100% donor cells (range, 50% to 100%). As yet,
no case of complete autologous recovery has been identiﬁed.
Acute GVHD
The cumulative incidence of grades II to IV acute
GVHD was 29% (Figure 1B). The GVHD seen was grade
II (21%), III (7%), or grade IV (1%).
Chronic GVHD
The cumulative incidence of chronic GVHD was 32%
(data not shown). In most patients, chronic GVHD responded
to therapy with complete responses (Figure 1C and D). Of the
patients with chronic GVHD, 83% are surviving (Figure 1D).
At a median of 2.6 years (range, 1.5-10 years) after transplan-
tation, 8 patients still require immunosuppressive therapy
for chronic GVHD.
Survival Rate
With a median follow-up of 6.0 years (range, 0.5-
11.6 years), the Kaplan-Meier estimate of survival was
88% (Figure 2).
Causes of Death
Eleven of the patients died at a median of 113 days
(range, 6-223 days) after transplantation. Patient 1 with a
4-year history of aplastic anemia died on day 6 with dissemi-
nated candidiasis, which preceded the transplantation.
Figure 1. Cumulative incidences of graft rejection (A) and developing
acute grade II to IV graft-versus-host disease (GVHD) (B) in patients
with aplastic anemia given HLA-identical marrow grafts following
cyclophosphamide/antithymocyte globulin and GVHD prophylaxis with
methotrexate/cyclosporine. (C) Prevalence of chronic GVHD. (D) Prob-
ability of survival among the 29 patients with chronic GVHD and proba-
bility of discontinuing immunosuppression given for chronic GVHD.
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Patient 2 died on day 45 from multiorgan failure following
septicemia. Patient 3 had a 13-year history of dyskeratosis
congenita and of pneumonia of unknown etiology 2 years
before transplantation. He showed diffuse interstitial thick-
ening of both lungs at transplantation. He died on day 70
from idiopathic interstitial fibrosis, which is a hallmark of
dyskeratosis congenita. Patient 4 died on day 72 from gas-
trointestinal hemorrhage. Patient 5 died during the course
of a community-based epidemic from respiratory syncytial
virus infection of the lungs on day 83. Patient 6 died on day
113 from multiorgan failure following an Epstein-Barr
virus–positive lymphoproliferative syndrome. This patient
had steroid-resistant grade IV acute GVHD for which he
was treated ﬁrst with an anti-CD3 monoclonal antibody and
then with rabbit ATG (Sangstat Medical Corp., Menlo Park,
CA). Patient 7 had progressive-onset chronic GVHD and
died on day 179 with a mixed Pseudomonas aeruginosa and
cytomegalovirus pneumonia. Patient 8 died at 199 days with
an Escherichia coli septicemia. Patient 9 died on day 223 from
bacterial septicemia. Patients 10 and 11 died with idiopathic
interstitial pneumonia on days 210 and 220, respectively.
Karnofsky Scores of Surviving Patients
The median Karnofsky score of surviving patients was
100%. One patient had a Karnofsky score of <80%, 6 of
80%, 14 of 90% to 95%, and 62 of 100%.
DISCUSSION
CY is an attractive conditioning agent for allogeneic mar-
row grafts in patients with aplastic anemia because the drug
does not appear to be marrow ablative [3]. Primate studies
showed that the dose-limiting toxicity of CY was cardiac toxic-
ity [3]. The ﬁnding of stable, long-term mixed donor-host
hematopoietic chimerism in CY-conditioned dogs [2] was not a
concern given that the marrows of patients with aplastic anemia
are empty, the disease is nonmalignant, and the persistence of a
few surviving host cells would not be expected to lead to recur-
rence of the underlying disease. Further, CY seemed a better
choice than regimens based on total body irradiation because it
promised a lessened risk of carcinogenicity [27]. This assump-
tion was borne out by clinical observations [28,29]. Also, CY
had fewer adverse effects on fertility and on growth and devel-
opment than did radiation-containing regimens [30-32].
Adding ATG to CY did not significantly increase the
acute toxicities of the conditioning regimen but apparently
provided increased immunosuppression as indicated by the
observed low incidence (4%) of graft rejection, even
though most patients had multiple preceding transfusions.
Consistent with initial observations [15], the current mul-
ticenter report reemphasizes that the regimen is both well
tolerated and effective, even in heavily pretreated patients
with an age range extending to almost 60 years. The over-
all survival rate has remained close to 90%. However,
although the use of CY/ATG is likely to have played a
major role in the lowered rejection incidence, other fac-
tors—such as prevention of sensitization to minor histo-
compatibility antigens through the use of leukopoor [33]
and in vitro irradiated [34,35] blood products—may also
have contributed. Several smaller studies by other centers
involving 10 to 16 patients have reported survival ranging
from 87% to 100% with the use of CY/ATG [36-38]. By
comparison, a recent large retrospective analysis by the
International Bone Marrow Transplant Registry of patients
with aplastic anemia given a variety of other conditioning
programs, including total and partial body irradiation,
showed survival ranging from 55% to 67% [39].
A number of recent publications have drawn attention
to the possibility that addition of ATG to the conditioning
regimens of patients undergoing transplantation for malig-
nant diseases reduced both the incidence and severity of
acute GVHD [40,41]. Previous work in experimental animal
models gave conﬂicting results with regard to the effect of
pretransplantation ATG on GVHD [42-48]. The current
study showed a 29% incidence of acute GVHD, a value that
was not signiﬁcantly different from the 20% incidence pre-
viously reported in MTX/CSP-treated aplastic anemia
patients conditioned by CY alone [15].
A feature not previously considered in analyses of the
inﬂuences of conditioning regimens on stable engraftment
has been the nature of the postgrafting immunosuppression.
Canine studies had shown MTX/CSP to be better than CSP
alone with respect to enhancing stable engraftment in
untransfused recipients given marginally immunosuppressive
conditioning treatment before transplantation [49]. Another
novel antimetabolite, mycophenolate mofetil (MMF), when
combined with CSP, was found to be even more effective
[49]. Thus, future evaluations of conditioning programs—in
particular, randomized comparisons of new pretransplanta-
tion regimens—will have to take the nature of the postgrafting
immunosuppression into account before drawing conclusions
about the effectiveness of any given regimen.
Regarding late complications, 1 patient in the current
study developed Epstein-Barr virus–positive lymphoprolif-
erative disease. This complication may have been the result
of treatment of the patient’s steroid-resistant acute GVHD
by an anti-CD3 monoclonal antibody followed by rabbit
ATG, rather than associated with the CY/ATG conditioning
regimen [50]. Currently, no other secondary malignancies
have been seen. Although CY is an alkylating agent with
known mutagenic capabilities, previous studies with longer
follow-up have documented that CY-conditioned patients
have a lessened rate of secondary malignancies compared
with those who received irradiation in addition to CY [29].
Also, although the follow-up of current patients is still short,
Figure 2. Kaplan-Meier curve of survival among the 94 patients who
underwent transplantation. The event-free survival rate was 85% (data
not shown). 
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it appears that the addition of ATG to the conditioning reg-
imen has not resulted in other untoward late effects.
The CY/ATG regimen is associated with acute toxic
side effects characteristic of other conventional conditioning
programs, such as nausea, vomiting, diarrhea, mucositis, and
fevers, for which hospitalization of the patients is required.
Further, as previously reported [15], transient reactions to
ATG were observed in 22 of the original 39 patients in the
form of skin rashes, fevers above 38.5°C, or arthralgias and
myalgias. Perhaps in the future, other less toxic immunosup-
pressive agents, eg, fludarabine, monoclonal antibodies to
the T-cell receptor, or second-signal blockade blockers
(cytotoxic T lymphocyte–associated antigen-4 immuno-
globulin [CTLA4-Ig], monoclonal antibody to CD40-
ligand), can be used as substitutes for high-dose CY/ATG.
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